相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- BVI announced successful completion of the first US implantations of its FineVision HP trifocal IOL by five leading cataract and refractive surgeons across the country. - The presbyopia-correcting lens received FDA approval in October 2025 and features a 3.5 diopter add power designed to enhance near vision while maintaining visual quality across all distances. - The IOL utilizes proprietary diffractive trifocal optic technology with hydrophobic materials optimized for long-term optical clarity and reduced halos and glare. - BVI plans to gradually expand access to the lens throughout the year as manufacturing capacity increases, following initial introduction to select surgeons.
- BVI's FINEVISION HP trifocal intraocular lens has received FDA approval for the US market, expanding advanced IOL options for American ophthalmologists and their patients. - The lens has been implanted in millions of procedures globally over 15 years and features diffractive optic design supporting vision at far, intermediate, and near distances. - A phased US rollout is planned starting fall 2025, with broader distribution expected in the first six months of 2026 as BVI scales manufacturing to meet anticipated demand. - The approval is supported by US clinical study data (NCT04176965) and represents a significant expansion of BVI's premium IOL portfolio in the American market.
